Viridian Therapeutics, Inc.\DE (VRDN) Operating Expenses (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Operating Expenses of $116.3 million for Q1 2026, up 23.82% year-over-year from $93.9 million in Q1 2025, and down 5.35% quarter-over-quarter from $122.9 million in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Operating Expenses (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Operating Expenses history runs 14 years deep, the most recent figure standing at $116.3 million for Q1 2026.
- In Q1 2026, Operating Expenses rose 23.82% year-over-year to $116.3 million; the TTM figure through Mar 2026 stood at $456.6 million (up 35.37% YoY), while the FY2025 annual figure was $434.2 million, up 45.07% from the prior year.
- Operating Expenses for Q1 2026 stood at $116.3 million, down from $122.9 million in the prior quarter.
- The five-year high for Operating Expenses was $122.9 million in Q4 2025, with the low at $26.1 million in Q1 2022.
- The 5-year median for Operating Expenses is $72.3 million (2024), against an average of $73.0 million.
- The sharpest annual moves came in 2023 and 2024: Operating Expenses surged 178.0% in 2023, then decreased 22.88% in 2024.
- Viridian Therapeutics, Inc.\DE's Operating Expenses stood at $49.2 million in 2022, then soared by 45.51% to $71.6 million in 2023, then advanced by 22.35% to $87.5 million in 2024, then soared by 40.36% to $122.9 million in 2025, then dropped by 5.35% to $116.3 million in 2026.
- Business Quant data shows VRDN's Operating Expenses at $116.3 million in Q1 2026, $122.9 million in Q4 2025, and $110.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | 126.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 126.55 Mn |
| Mar 31, 2026 | 116.31 Mn |
| Dec 31, 2025 | 122.88 Mn |
| Sep 30, 2025 | 110.58 Mn |
| Jun 30, 2025 | 106.84 Mn |
| Mar 31, 2025 | 93.94 Mn |
| Dec 31, 2024 | 87.54 Mn |
| Sep 30, 2024 | 83.57 Mn |
| Jun 30, 2024 | 72.26 Mn |
| Mar 31, 2024 | 55.97 Mn |
| Dec 31, 2023 | 71.55 Mn |
| Sep 30, 2023 | 51.30 Mn |
| Jun 30, 2023 | 59.35 Mn |
| Mar 31, 2023 | 72.57 Mn |
| Dec 31, 2022 | 49.17 Mn |
| Sep 30, 2022 | 30.98 Mn |
| Jun 30, 2022 | 29.82 Mn |
| Mar 31, 2022 | 26.11 Mn |
| Dec 31, 2021 | 29.30 Mn |
| Sep 30, 2021 | 14.34 Mn |